{"title":"开发用于上皮性卵巢癌患者总体生存的机器学习预后模型:一项基于预言家的研究。","authors":"Jianing Fan, Yu Jiang, Xinyan Wang, Juan Lyv","doi":"10.1080/14737140.2025.2465903","DOIUrl":null,"url":null,"abstract":"<p><strong>Research design and methods: </strong>Data were obtained from the SEER database for women diagnosed with EOC between 2004 and 2020. Clinical features, treatment regimens and overall survival (OS) were analyzed. Cox regression was conducted to identify prognostic factors associated with EOC. We employed 5-fold cross-validation to improve the accuracy of the model. Random Survival Forest (RSF), Gradient Boosting Survival Analysis (GBSA) and Support Vector Machine (SVM) were used to develop ML models, then compared with the Cox model. The predictive performance of these models was assessed using AUC, concordance index (C-index), and Brier scores.</p><p><strong>Results: </strong>A total of 12,949 EOC patients were selected from the SEER database. We identified 14 independent prognostic factors for OS and constructed predictive models. The GBSA model demonstrated superior AUC, C-index, and Brier scores across different time points, outperforming the Cox model. SHAP analysis showed that FIGO stage, grade, and lymph node dissection were the most important features in the GBSA model.</p><p><strong>Conclusions: </strong>The GBSA model outperforms traditional methods in survival prediction, offering a valuable tool for clinicians to make informed decisions about patient prognosis.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of machine learning prognostic models for overall survival of epithelial ovarian cancer patients: a SEER-based study.\",\"authors\":\"Jianing Fan, Yu Jiang, Xinyan Wang, Juan Lyv\",\"doi\":\"10.1080/14737140.2025.2465903\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Research design and methods: </strong>Data were obtained from the SEER database for women diagnosed with EOC between 2004 and 2020. Clinical features, treatment regimens and overall survival (OS) were analyzed. Cox regression was conducted to identify prognostic factors associated with EOC. We employed 5-fold cross-validation to improve the accuracy of the model. Random Survival Forest (RSF), Gradient Boosting Survival Analysis (GBSA) and Support Vector Machine (SVM) were used to develop ML models, then compared with the Cox model. The predictive performance of these models was assessed using AUC, concordance index (C-index), and Brier scores.</p><p><strong>Results: </strong>A total of 12,949 EOC patients were selected from the SEER database. We identified 14 independent prognostic factors for OS and constructed predictive models. The GBSA model demonstrated superior AUC, C-index, and Brier scores across different time points, outperforming the Cox model. SHAP analysis showed that FIGO stage, grade, and lymph node dissection were the most important features in the GBSA model.</p><p><strong>Conclusions: </strong>The GBSA model outperforms traditional methods in survival prediction, offering a valuable tool for clinicians to make informed decisions about patient prognosis.</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-02-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2465903\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2465903","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Development of machine learning prognostic models for overall survival of epithelial ovarian cancer patients: a SEER-based study.
Research design and methods: Data were obtained from the SEER database for women diagnosed with EOC between 2004 and 2020. Clinical features, treatment regimens and overall survival (OS) were analyzed. Cox regression was conducted to identify prognostic factors associated with EOC. We employed 5-fold cross-validation to improve the accuracy of the model. Random Survival Forest (RSF), Gradient Boosting Survival Analysis (GBSA) and Support Vector Machine (SVM) were used to develop ML models, then compared with the Cox model. The predictive performance of these models was assessed using AUC, concordance index (C-index), and Brier scores.
Results: A total of 12,949 EOC patients were selected from the SEER database. We identified 14 independent prognostic factors for OS and constructed predictive models. The GBSA model demonstrated superior AUC, C-index, and Brier scores across different time points, outperforming the Cox model. SHAP analysis showed that FIGO stage, grade, and lymph node dissection were the most important features in the GBSA model.
Conclusions: The GBSA model outperforms traditional methods in survival prediction, offering a valuable tool for clinicians to make informed decisions about patient prognosis.
期刊介绍:
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.